The U.S. Food and Drug Administration said it approved Vertex Pharmaceuticals' Journavx for short-term pain that often ...
With a rise in Trikafta demand, the investors have assigned a higher valuation multiple for VRTX stock. The increase in VRTX ...
Analyst Andrew Fein of H.C. Wainwright maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report), boosting the price target to ...
Suzetrigine (Journavx) is the first non-opioid painkiller to be approved in the US in 20 years. It could help over 80 million ...